Idactamab

Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5) [1][2].

Product Specifications

CAS Number

[2245205-37-0]

Product Name Alternative

INT-001

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/idactamab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Idactamab]

Molecular Weight

(146.54 kDa)

References & Citations

[1]Pore N, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD) -based antibody drug conjugate targeting ASCT2, for treating hematological cancers[J]. Blood, 2018, 132: 4071.|[2]Monks N R, et al. Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies[J]. Cancer Research, 2018, 78 (13_Supplement) : LB-295-LB-295.